CARRINGTON PAUL E,DENG QIAOLIN,NARGUND RAVI,PALANI ANANDAN,TUCKER THOMAS JOSEPH,WU CHENGWEI,BIANCHI ELISABETTA,ORVIETO FEDERICA,PESSI ANTONELLO
申请号：
IN201747013446
公开号：
IN201747013446A
申请日:
2017.04.16
申请国别(地区):
IN
年份:
2017
代理人:
摘要：
Described are peptide analogs of glucagon which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP IV) and to increase in vivo half life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon like peptide 1 (GLP 1) receptor and the glucagon (GCG) receptor and the use of such GLP 1 receptor/GCG receptor co agonists for treatment of metabolic disorders such as diabetes non alcoholic fatty liver disease (NAFLD) non alcoholic steatohepatitis (NASH) and obesity
